Pharming Launches Joenja In Japan For APDS
(RTTNews) - Pharming Group (PHAR) announced the commercial launch of Joenja (leniolisib) in Japan for adult and children aged 4 years and older with activated PI3K delta syndrome, following its inclusion in NHI price list. Activated PI3K delta syndrome (APDS) is a rare primary …
Sharemaestro market context Price below Trend Line 52 weeks -14.5%